Skip to main content

Table 1 Patient characteristics by initial GC dose group

From: Treatment-related damage in elderly-onset ANCA-associated vasculitis: safety outcome analysis of two nationwide prospective cohort studies

 

Low-dose (n = 59)

Medium-dose (n = 52)

High-dose (n = 68)

Male/female

27/32

18/34

23/45

Age (years), mean ± SD (median)

80.9 ± 3.9 (80)

79.9 ± 3.6 (80)

79.1 ± 3.6 (78)

Disease classification, n

 EGPA

2

2

3

 GPA

5

9

14

 MPA

42

33

38

 Unclassifiable

10

8

13

Disease severity, n (%)

 Localized

1

3

3

 Early systemic

12

14

18

 Systemic

34

27

35

 Severe

12

8

12

BVAS, mean ± SD

15.8 ± 6.3

17.3 ± 6.0

15.4 ± 7.2

MPO-ANCA–positive, n (%)

55 (93)

49 (94)

64 (94)

PR3-ANCA–positive, n (%)

0

2 (4)

3 (4)

Serum creatinine (mg/dL), mean ± SD

3.11 ± 3.56

2.36 ± 2.15

1.59 ± 1.31

Interstitial lung disease, n (%)

29 (49)

24 (46)

29 (43)

Treatment

 Initial daily dose of PSL (mg/kg/day), mean ± SD#, †

0.47 ± 0.10

0.69 ± 0.05

0.98 ± 0.18

 Cyclophosphamide, n (%)

8 (13)

10 (19)

36 (53)

  1. Comparisons among groups were made using the Mann–Whitney U test or Fisher’s exact probability test. Statistical significance was determined by using Bonferroni correction (< 0.05/3). ANCA antineutrophil cytoplasmic antibody, BVAS Birmingham Vasculitis Activity Score, EGPA eosinophilic granulomatosis with polyangiitis, GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis, MPO myeloperoxidase, PR3 proteinase 3, PSL prednisolone, SD standard deviation
  2. #Medium-dose vs. high-dose group
  3. Low-dose vs. high-dose group